

GSK plc (the 'Company')
Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')								
a)	Name	Emma Walmsley							
b)	Position/status	Chief Executive Officer							
c)	Initial notification/ amendment	Initial notification							
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor								
a)	Name	GSK plc							
b)	LEI	5493000HZTVUYLO1D793							
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted								
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63							
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan							
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>£14.2073</td><td>8 (partnership shares)</td></tr><tr><td>£14.2073</td><td>8 (matching shares)</td></tr></table>	Price(s)	Volume(s)	£14.2073	8 (partnership shares)	£14.2073	8 (matching shares)	
Price(s)	Volume(s)								
£14.2073	8 (partnership shares)								
£14.2073	8 (matching shares)								
d)	Aggregated information								
	Aggregated volume Price	16 Ordinary Shares £14.2073							
e)	Date of the transaction	2025-07-09							
f)	Place of the transaction	London Stock Exchange (XLON)							

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Julie Brown
b)	Position/status	Chief Financial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	

a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.2073	9 (partnership shares)
		£14.2073	9 (matching shares)
d)	Aggregated information		
	Aggregated volume	18 Ordinary Shares	
	Price	£14.2073	
e)	Date of the transaction	2025-07-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	James Ford	
b)	Position/status	SVP and Group General Counsel, Legal and Compliance	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.2073	9 (partnership shares)
		£14.2073	9 (matching shares)
d)	Aggregated information		
	Aggregated volume	18 Ordinary Shares	

	Price	£14.2073
e)	Date of the transaction	2025-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Sally Jackson	
b)	Position/status	SVP, Global Communications and CEO Office	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.2073	9 (partnership shares)
		£14.2073	9 (matching shares)
d)	Aggregated information		
	Aggregated volume Price	18 Ordinary Shares £14.2073	
e)	Date of the transaction	2025-07-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793

3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.2073	9 (partnership shares)
		£14.2073	9 (matching shares)
d)	Aggregated information		
	Aggregated volume Price	18 Ordinary Shares £14.2073	
e)	Date of the transaction	2025-07-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Regis Simard	
b)	Position/status	President, Global Supply Chain	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.2073	9 (partnership shares)
		£14.2073	9 (matching shares)
d)	Aggregated information		
	Aggregated volume Price	18 Ordinary Shares £14.2073	
e)	Date of the	2025-07-09	

	transaction	
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Philip Thomson	
b)	Position/status	President, Global Affairs	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.2073	9 (partnership shares)
		£14.2073	9 (matching shares)
d)	Aggregated information		
	Aggregated volume	18 Ordinary Shares	
	Price	£14.2073	
e)	Date of the transaction	2025-07-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where	

	transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.2073	9 (partnership shares)
		£14.2073	9 (matching shares)
d)	Aggregated information		
	Aggregated volume Price	18 Ordinary Shares £14.2073	
e)	Date of the transaction	2025-07-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Victoria Whyte	
b)	Position/status	Company Secretary	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.2073	9 (partnership shares)
		£14.2073	9 (matching shares)
d)	Aggregated information		
	Aggregated volume Price	18 Ordinary Shares £14.2073	
e)	Date of the transaction	2025-07-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

--	--	--

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Emma Walmsley	
b)	Position/status	Chief Executive Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025 on shares held through the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s) £14.4447	Volume(s) 32
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-07-10	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Diana Conrad
b)	Position/status	Chief People Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63

b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025 on shares held through the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.4447	5
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2025-07-10	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	James Ford	
b)	Position/status	SVP and Group General Counsel, Legal and Compliance	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025 on shares held through the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.4447	12
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-07-10	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Sally Jackson
b)	Position/status	SVP, Global Communications and CEO Office

c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO1D793				
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted					
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025 on shares held through the Company's Share Reward Plan				
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>£14.4447</td><td>21</td></tr></table>	Price(s)	Volume(s)	£14.4447	21
Price(s)	Volume(s)					
£14.4447	21					
d)	Aggregated information Aggregated volume Price	N/A (single transaction)				
e)	Date of the transaction	2025-07-10				
f)	Place of the transaction	London Stock Exchange (XLON)				

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Luke Miels	
b)	Position/status	Chief Commercial Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025 on shares held through the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s) £14.4447	Volume(s) 3
d)	Aggregated	N/A (single transaction)	

	information	
	Aggregated volume Price	
e)	Date of the transaction	2025-07-10
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	David Redfern	
b)	Position/status	President Corporate Development	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025 on shares held through the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.4447	84
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-07-10	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793

3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted					
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025 on shares held through the Company's Share Reward Plan				
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>£14.4447</td><td>32</td></tr></table>	Price(s)	Volume(s)	£14.4447	32
Price(s)	Volume(s)					
£14.4447	32					
d)	Aggregated information Aggregated volume Price	N/A (single transaction)				
e)	Date of the transaction	2025-07-10				
f)	Place of the transaction	London Stock Exchange (XLON)				

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Philip Thomson	
b)	Position/status	President, Global Affairs	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025 on shares held through the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s) £14.4447	Volume(s) 54
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-07-10	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Deborah Waterhouse	
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025 on shares held through the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s) £14.4447	Volume(s) 70
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-07-10	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Victoria Whyte
b)	Position/status	Company Secretary
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the	Acquisition of Ordinary Shares following the re-investment of

	transaction	dividends paid to shareholders on 10 July 2025 on shares held through the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.4447	65
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume		
	Price		
e)	Date of the transaction	2025-07-10	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Emma Walmsley	
b)	Position/status	Chief Executive Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.5450	1,708
		£14.5450	1,511
		£14.5450	1,158
d)	Aggregated information		
	Aggregated volume	4,377	
	Price	£14.5450	
e)	Date of the transaction	2025-07-10	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')
----	--

a)	Name	Julie Brown							
b)	Position/status	Chief Financial Officer							
c)	Initial notification/ amendment	Initial notification							
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor								
a)	Name	GSK plc							
b)	LEI	5493000HZTVUYLO1D793							
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted								
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63							
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan							
c)	Price(s) and volume(s)	<table><tr><th>Price(s)</th><th>Volume(s)</th></tr><tr><td>£14.5450</td><td>651</td></tr><tr><td>£14.5450</td><td>758</td></tr></table>	Price(s)	Volume(s)	£14.5450	651	£14.5450	758	
Price(s)	Volume(s)								
£14.5450	651								
£14.5450	758								
d)	Aggregated information								
	Aggregated volume Price	1,409 £14.5450							
e)	Date of the transaction	2025-07-10							
f)	Place of the transaction	London Stock Exchange (XLON)							

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Diana Conrad
b)	Position/status	Chief People Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the	Increase in notional interest in Ordinary Shares following the re-

	transaction	investment of dividends paid to shareholders on 10 July 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan									
c)	Price(s) and volume(s)	<table><tr><th>Price(s)</th><th>Volume(s)</th></tr><tr><td>£14.5450</td><td>169</td></tr><tr><td>£14.5450</td><td>275</td></tr><tr><td>£14.5450</td><td>430</td></tr></table>	Price(s)	Volume(s)	£14.5450	169	£14.5450	275	£14.5450	430	
Price(s)	Volume(s)										
£14.5450	169										
£14.5450	275										
£14.5450	430										
d)	Aggregated information										
	Aggregated volume	874									
	Price	£14.5450									
e)	Date of the transaction	2025-07-10									
f)	Place of the transaction	London Stock Exchange (XLON)									

1.	Details of PDMR/person closely associated with them ('PCA')										
a)	Name	James Ford									
b)	Position/status	SVP and Group General Counsel, Legal and Compliance									
c)	Initial notification/ amendment	Initial notification									
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor										
a)	Name	GSK plc									
b)	LEI	5493000HZTVUYLO1D793									
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted										
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63									
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan									
c)	Price(s) and volume(s)	<table><tr><th>Price(s)</th><th>Volume(s)</th></tr><tr><td>£14.5450</td><td>267</td></tr><tr><td>£14.5450</td><td>436</td></tr><tr><td>£14.5450</td><td>264</td></tr></table>	Price(s)	Volume(s)	£14.5450	267	£14.5450	436	£14.5450	264	
Price(s)	Volume(s)										
£14.5450	267										
£14.5450	436										
£14.5450	264										
d)	Aggregated information										
	Aggregated volume	967									
	Price	£14.5450									
e)	Date of the transaction	2025-07-10									
f)	Place of the transaction	London Stock Exchange (XLON)									

1.	Details of PDMR/person closely associated with them ('PCA')										
a)	Name	Sally Jackson									
b)	Position/status	SVP, Global Communications and CEO Office									
c)	Initial notification/ amendment	Initial notification									
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor										
a)	Name	GSK plc									
b)	LEI	5493000HZTVUYLO1D793									
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted										
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63									
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan									
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>£14.5450</td><td>270</td></tr><tr><td>£14.5450</td><td>148</td></tr><tr><td>£14.5450</td><td>166</td></tr></table>	Price(s)	Volume(s)	£14.5450	270	£14.5450	148	£14.5450	166	
Price(s)	Volume(s)										
£14.5450	270										
£14.5450	148										
£14.5450	166										
d)	Aggregated information										
	Aggregated volume	584									
	Price	£14.5450									
e)	Date of the transaction	2025-07-10									
f)	Place of the transaction	London Stock Exchange (XLON)									

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Luke Miels
b)	Position/status	Chief Commercial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63

b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan									
c)	Price(s) and volume(s)	<table><tr><th>Price(s)</th><th>Volume(s)</th></tr><tr><td>£14.5450</td><td>811</td></tr><tr><td>£14.5450</td><td>407</td></tr><tr><td>£14.5450</td><td>644</td></tr></table>	Price(s)	Volume(s)	£14.5450	811	£14.5450	407	£14.5450	644	
Price(s)	Volume(s)										
£14.5450	811										
£14.5450	407										
£14.5450	644										
d)	Aggregated information										
	Aggregated volume	1,862									
	Price	£14.5450									
e)	Date of the transaction	2025-07-10									
f)	Place of the transaction	London Stock Exchange (XLON)									

1.	Details of PDMR/person closely associated with them ('PCA')										
a)	Name	Shobie Ramakrishnan									
b)	Position/status	Chief Digital and Technology Officer									
c)	Initial notification/ amendment	Initial notification									
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor										
a)	Name	GSK plc									
b)	LEI	5493000HZTVUYLO1D793									
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted										
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044									
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 10 July 2025 on ADSs held in the Company's Deferred Annual Bonus Plan									
c)	Price(s) and volume(s)	<table><tr><th>Price(s)</th><th>Volume(s)</th></tr><tr><td>39.5800</td><td>131</td></tr><tr><td>39.5800</td><td>123</td></tr><tr><td>39.5800</td><td>204</td></tr></table>	Price(s)	Volume(s)	39.5800	131	39.5800	123	39.5800	204	
Price(s)	Volume(s)										
39.5800	131										
39.5800	123										
39.5800	204										
d)	Aggregated information										
	Aggregated volume	458									
	Price	39.5800									
e)	Date of the	2025-07-10									

	transaction	
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')										
a)	Name	David Redfern									
b)	Position/status	President, Corporate Development									
c)	Initial notification/ amendment	Initial notification									
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor										
a)	Name	GSK plc									
b)	LEI	5493000HZTVUYLO1D793									
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted										
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63									
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan									
c)	Price(s) and volume(s)	<table><tr><th>Price(s)</th><th>Volume(s)</th></tr><tr><td>£14.5450</td><td>372</td></tr><tr><td>£14.5450</td><td>516</td></tr><tr><td>£14.5450</td><td>235</td></tr></table>	Price(s)	Volume(s)	£14.5450	372	£14.5450	516	£14.5450	235	
Price(s)	Volume(s)										
£14.5450	372										
£14.5450	516										
£14.5450	235										
d)	Aggregated information										
	Aggregated volume	1,123									
	Price	£14.5450									
e)	Date of the transaction	2025-07-10									
f)	Place of the transaction	London Stock Exchange (XLON)									

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793

3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63		
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		£14.5450	345	
		£14.5450	622	
		£14.5450	299	
d)	Aggregated information			
	Aggregated volume	1,266		
	Price	£14.5450		
e)	Date of the transaction	2025-07-10		
f)	Place of the transaction	London Stock Exchange (XLON)		

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Philip Thomson	
b)	Position/status	President, Global Affairs	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.5450	195
		£14.5450	209
		£14.5450	347

d)	Aggregated information	
	Aggregated volume	751
	Price	£14.5450
e)	Date of the transaction	2025-07-10
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')										
a)	Name	Deborah Waterhouse									
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK									
c)	Initial notification/ amendment	Initial notification									
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor										
a)	Name	GSK plc									
b)	LEI	5493000HZTVUYLO1D793									
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted										
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63									
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan									
c)	Price(s) and volume(s)	<table><tr><th>Price(s)</th><th>Volume(s)</th></tr><tr><td>£14.5450</td><td>476</td></tr><tr><td>£14.5450</td><td>324</td></tr><tr><td>£14.5450</td><td>538</td></tr></table>	Price(s)	Volume(s)	£14.5450	476	£14.5450	324	£14.5450	538	
Price(s)	Volume(s)										
£14.5450	476										
£14.5450	324										
£14.5450	538										
d)	Aggregated information										
	Aggregated volume	1,338									
	Price	£14.5450									
e)	Date of the transaction	2025-07-10									
f)	Place of the transaction	London Stock Exchange (XLON)									

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Tony Wood
b)	Position/status	Chief Scientific Officer
c)	Initial notification/ amendment	Initial notification

2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.5450	662
		£14.5450	302
		£14.5450	226
d)	Aggregated information		
	Aggregated volume Price	1,190 £14.5450	
e)	Date of the transaction	2025-07-10	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Emma Walmsley	
b)	Position/status	Chief Executive Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025 on Ordinary Shares held in the Company's Performance Share Plan subject to a 2-year holding period	
c)	Price(s) and volume(s)	Price(s)	Volume(s)

		£14.5450	4,680.094
		£14.5450	5,119.467
d)	Aggregated information Aggregated volume Price	N/A (single transaction) 9,799.561 £14.5450	
e)	Date of the transaction	2025-07-10	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Elizabeth McKee Anderson	
b)	Position/status	Independent Non-Executive Director	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044	
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 July 2025	
c)	Price(s) and volume(s)	Price(s) 38.5396	Volume(s) 27
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-07-11	
f)	Place of the transaction	New York Stock Exchange (XNYS)	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Charles Bancroft
b)	Position/status	Senior Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification

2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044	
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 July 2025	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		38.5396	364
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume		
	Price		
e)	Date of the transaction	2025-07-11	
f)	Place of the transaction	New York Stock Exchange (XNYS)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Dr Hal Barron	
b)	Position/status	Non-Executive Director	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044	
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 July 2025	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		38.5396	30
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume		
	Price		

e)	Date of the transaction	2025-07-11
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Dr Anne Beal	
b)	Position/status	Independent Non-Executive Director	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044	
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 July 2025	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		38.5396	35
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2025-07-11	
f)	Place of the transaction	New York Stock Exchange (XNYS)	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Dr Harry Dietz
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where	

	transaction(s) has been conducted		
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044	
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 July 2025	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		38.5396	34
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2025-07-11	
f)	Place of the transaction	New York Stock Exchange (XNYS)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Dr Jeannie Lee	
b)	Position/status	Independent Non-Executive Director	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044	
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 July 2025	
c)	Price(s) and volume(s)	Price(s) 38.5396	Volume(s) 11
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-07-11	
f)	Place of the transaction	New York Stock Exchange (XNYS)	

1.	Details of PDMR/person closely associated with them ('PCA')						
a)	Name	Dr Vishal Sikka					
b)	Position/status	Independent Non-Executive Director					
c)	Initial notification/ amendment	Initial notification					
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name	GSK plc					
b)	LEI	5493000HZTVUYLO1D793					
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted						
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044					
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 July 2025					
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>38.5396</td><td>103</td></tr></table>	Price(s)	Volume(s)	38.5396	103	
Price(s)	Volume(s)						
38.5396	103						
d)	Aggregated information Aggregated volume Price	N/A (single transaction)					
e)	Date of the transaction	2025-07-11					
f)	Place of the transaction	New York Stock Exchange (XNYS)					

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	David Redfern
b)	Position/status	President Corporate Development
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025, on Ordinary Shares held within an ISA

		held within an ISA	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.3784	23
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2025-07-11	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Victoria Whyte	
b)	Position/status	Company Secretary	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025, on Ordinary Shares held within an ISA	
c)	Price(s) and volume(s)	Price(s) £14.3784	Volume(s) 19
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-07-11	
f)	Place of the transaction	London Stock Exchange (XLON)	

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHSFAFLLEISESW